Evidence map›Paper›PMID 41895229›Full record

ArticleMolecular pharmacology2026

Loss of α-cell GRK2 modulates glucagon response and supports cardiac function.

Jonathan Snyder, Lilly Underwood, Chun-Sun Jiang, Victoria Kaml, Snekha Rajasekaran, Lily Xie, C Reid Dotson, Priscila Y Sato

Abstract read
In one paragraph

Article in Molecular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan SnyderDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania.
Lilly UnderwoodDepartment of Medicine, Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama.
Chun-Sun JiangDepartment of Medicine, Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama.
Victoria KamlDepartment of Medicine, Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama.
Snekha RajasekaranDepartment of Medicine, Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama.
Lily XieDepartment of Medicine, Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama.
C Reid DotsonDepartment of Medicine, Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama.
Priscila Y SatoDepartment of Medicine, Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: psato@uab.edu.

Funding

Dysregulation of cardiac signaling in disease and stressR01HL163666 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Priscila Sato · 2022 to 2026
$2.0M
Non-canonical role of GRK2 in mediating cardiac functionR56HL149887 · NHLBI · DREXEL UNIVERSITY · PI SATO, PRISCILA · 2021 to 2021
$630k
NHLBI NIH HHS R01 HL163666NHLBI NIH HHS R56 HL149887
6 · The paper itself

Abstract

Pancreatic α-cells secrete glucagon to maintain glucose homeostasis, yet the molecular mechanisms regulating hormone release are understudied. G-protein coupled receptor kinases (GRKs) regulate receptor desensitization; however, their role in α-cells remains unknown. Here, we generated an inducible α-cell-specific GRK2 knockout (αGRK2KO) mouse model to investigate the role of GRK2 in islet physiology, systemic metabolism, and cardiac function. Loss of GRK2 in α-cells reduced islet GRK2 protein by ∼20%, consistent with α-cell islet abundance, and produced negligible alterations in glucose tolerance without affecting insulin secretion. Notably, αGRK2KO mice had altered fast/fed glucagon responses, reduced adiposity, and lower body weight. Despite minimal effects on systemic glucose handling, αGRK2KO animals exhibited improved cardiac function, characterized by enhanced ejection fraction and fractional shortening, without signs of hypertrophy. High-fat, high-sucrose diet feeding abated these changes, underscoring the diet-dependent impact of α-cell GRK2. Together, these findings identify GRK2 as a previously unrecognized regulator of α-cell glucagon secretion that influences systemic energy balance and cardiac performance through endocrine crosstalk. This work establishes a framework for α-cell G protein-coupled receptor regulation and highlights GRK2 as a potential therapeutic node linking islet function, metabolism, and the heart. SIGNIFICANCE STATEMENT: This study explores the role of GRK2 in α-cell biology as a regulator of glucagon dynamics and cardiac function, thereby establishing a new endocrine link between islet signaling and cardiac biology.

Indexed as

GlucagonGlucagon-Secreting CellsG-Protein-Coupled Receptor Kinase 2HeartAnimalsGlucoseInsulinMaleMiceMice, Inbred C57BLMice, KnockoutGlucagonGlucoseG-Protein-Coupled Receptor Kinase 2GRK2 protein, mouseInsulinGlucagonGRK2HeartInter-organ crosstalkIsletMetabolism

Identifiers

PMID41895229
PMCPMC13688967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.